METACARD MR

Trimetazidine Hydrochloride

Description:

Metacard MR Tablet (Trimetazidine Hydrochloride) is the new twice-daily formulation of the first 3- keto acyl CoA thiolase inhibitor (KAT), a metabolic anti-ischemic agent with proven benefits for all coronary patients.

Composition:

Metacard MR Tablet: Each modified release tablet contains Trimetazidine Hydrochloride BP 35 mg.

Pharmacology:

By preserving the energy metabolism in cells exposed to hypoxia or ischemia, trimetazidine prevents a decrease in intracellular ATP levels, thereby ensuring the proper functioning of ionic pumps and transmembranous sodium-potassium flow whilst maintaining cellular homeostasis.

In man: Controlled studies in angina patients have shown that trimetazidine increases coronary flow reserve, thereby delaying the onset of ischemia associated with exercise, limits rapid swings in blood pressure without any significant variations in heart rate, significantly decreases the frequency of angina attacks, and leads to a significant decrease in the use of nitrates.

Indication:

Metacard MR Tablet is a metabolic treatment for ischaemic heart disease. It can be used at all stages of angina pectoris and in post myocardial infarction. Metacard MR therapy has also demonstrated beneficial effects when administered during bypass surgery.

Dosage and Administration:

One tablet at mealtimes in the morning and evening.

Contraindication:

Trimetazidine is contraindicated in-patients with a known hypersensitivity to its components.

Side-effects:

Trimetazidine is safe and well tolerated. Rare cases of gastrointestinal disorders, nausea & vomiting have been reported.

Drug Interaction:

No drug interactions so far have been reported. In particular, no interactions have been reported with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidaemic agents or digitalis preparation.

Use in Pregnancy & Lactation:

Studies in animals have not demonstrated teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy. In the absence of data, breastfeeding is not recommended during treatment.

Packing: